Use of Clonidine in Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder Comorbidity: Report of 3 Cases

Clonidine has been widely used in child and adolescent psychiatry, especially in attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), which are recently categorized under neurodevelopmental disorders. However, it is not recommended as a first-line medication for treatm...

Full description

Saved in:
Bibliographic Details
Published inPsychiatry and clinical psychopharmacology Vol. 33; no. 4; pp. 326 - 329
Main Authors Temeltürk, Rahime Duygu, İlçioğlu Ekici, Gökçen, Yağmur Efendi, Gökçe, Kılıç, Birim Günay
Format Journal Article
LanguageEnglish
Published England Mesut Çetin 01.12.2023
AVES
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Clonidine has been widely used in child and adolescent psychiatry, especially in attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), which are recently categorized under neurodevelopmental disorders. However, it is not recommended as a first-line medication for treatment, and current data on the use of clonidine are limited. Herein, we present 3 cases with ADHD and ASD comorbidity, if any, as well as other neurodevelopmental disorders, including intellectual disability and Tourette's disorder, treated with clonidine. At the second-month follow-up, substantial improvements were observed in subscale scores of Conners's Parent Rating Scale-Revised Long Form, and Autism Behavior Checklist. Our case report indicated that clonidine is well tolerated, safe, and effective in improving both ADHD- and ASD-related symptoms as well as disruptive, aggressive behaviors and tics in children with multiple neurodevelopmental disorders.
Bibliography:Cite this article as: Temeltürk RD, İlçioğlu Ekici G, Efendi GY, Kılıç BG. Use of clonidine in attention deficit hyperactivity disorder and autism spectrum disorder comorbidity: Report of 3 cases. Psychiatry Clin Psychopharmacol. 2023;33(4):326-329.
ISSN:2475-0581
DOI:10.5152/pcp.2023.23690